What the research found

The widely-cited claim that tirzepatide users plateau around 30% weight loss appears to lack direct support in published trial data. The SURMOUNT-1 trial, which forms the basis of most tirzepatide efficacy claims, measured weight loss at intervals up to 25% — not 30%. At 72 weeks on the 15 mg dose, the mean reduction was approximately 21%, but this average masks considerable individual variation: 57% of participants exceeded 20% loss, and 36% surpassed 25%.

Plateau timing, not a hard ceiling, appears to be the real constraint. Most participants on active drug reached their individual weight-loss plateau between 6 and 9 months of treatment. The trajectory varied by baseline characteristics — those starting at higher BMI, on higher doses, younger, or female tended to continue losing for longer before plateauing. One participant in the trial achieved approximately 50% weight loss, demonstrating that individual outcomes can substantially exceed the average.

Why it matters for you

If you're tracking weight loss on tirzepatide and worried about hitting an immovable wall, the evidence suggests the issue is plateau, not refusal. You'll likely reach your personal nadir somewhere between months 6–9, then stabilise — not because the drug stops working, but because your body's new set-point has been reached. That endpoint depends on dose, age, sex, and starting BMI, not a universal ceiling.

This also reframes the maintenance question many MyKine users face. If you plateau at, say, 22% loss and your target is 25%, the question isn't "will my body refuse?" but rather "do I need a higher dose, or is this my physiological endpoint at this dose?" Those are different clinical conversations. Long-term data (mentioned but not detailed in the source) exist but aren't fully summarised here — worth asking your provider specifically about maintenance outcomes, not just weight-loss endpoints.

Caveats

• The 30% figure circulating clinically may come from secondary analyses, guidelines, or clinical practice patterns — the source only confirms it's absent from the main SURMOUNT-1 publication
• SURMOUNT-1 had a defined end-point (72 weeks); longer-term weight trajectories beyond that window require the extension data, which isn't detailed here
• Individual variation is large; your plateau point cannot be predicted from group means
• The source does not provide effect-size comparisons across dose levels or long-term maintenance data detail